AbbVie’s $10.9 B Cash Offer for Apogee at 49% Premium Faces Fairness Probe
APGE•AbbVie agreed to acquire Apogee Therapeutics for $10.9 billion in cash, offering $135.11 per share, a 49% premium to the prior close. Investor rights attorneys have launched an investigation into the fairness of the deal’s terms for Apogee shareholders.
1. Acquisition Terms
AbbVie will pay $10.9 billion in cash for Apogee with an offer of $135.11 per share, representing a 49% premium to the previous closing price, making it AbbVie’s largest acquisition in over five years.
2. Fairness Investigation
Investor rights law firms have initiated an investigation into whether the deal’s terms adequately protect Apogee shareholders, with potential challenges to seek increased consideration or additional disclosures before the transaction closes.
3. Drug Development Outlook
Apogee’s lead asset, zumilokibart, is set for a phase three trial in atopic dermatitis later this year, targeting a market dominated by Dupixent and presenting potential applications in asthma and other inflammatory conditions.
